**Table S1. Overall and Individual System Scores by Survivorship-focused vs. Other Providers**

|  | **All Groups** | **OTHER** | **SURVIVE** | **P-value\*\*** | **Test** |
| --- | --- | --- | --- | --- | --- |
|  | N=77 | N=56 | N=21 |  |  |
| OVERALL\_SCORE |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 8.0(6.0-13.0) | 8.0(6.0-12.0) | 9.0(7.0-13.0) |  |  |
| **I\_UPDATED\_IMMU** |  |  |  | 0.24 | Chi-square |
| NO | 4(5.2%) | 4(7.1%) | 0 |  |  |
| YES | 50(64.9%) | 37(66.1%) | 13(61.9%) |  |  |
| Missing | 23(29.9%) | 15(26.8%) | 8(38.1%) |  |  |
| **I\_IMMU\_NA** |  |  |  | 0.14 | Chi-square |
| NO | 60(77.9%) | 46(82.1%) | 14(66.7%) |  |  |
| YES | 17(22.1%) | 10(17.9%) | 7(33.3%) |  |  |
| **OC\_CLINCAL\_ASS** |  |  |  | 0.12 | Chi-square |
| NO | 51(66.2%) | 40(71.4%) | 11(52.4%) |  |  |
| YES | 26(33.8%) | 16(28.6%) | 10(47.6%) |  |  |
| **OC\_EXAM** |  |  |  | <0.01 | Chi-square |
| NO | 60(77.9%) | 49(87.5%) | 11(52.4%) |  |  |
| YES | 17(22.1%) | 7(12.5%) | 10(47.6%) |  |  |
| **OCULAR\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 0.0(0.0-2.0) | 0.0(0.0-2.0) | 1.0(0.0-2.0) |  |  |
| **OR\_EDU** |  |  |  | <0.01 | Chi-square |
| NO | 70(90.9%) | 55(98.2%) | 15(71.4%) |  |  |
| YES | 7(9.1%) | 1(1.8%) | 6(28.6%) |  |  |
| **OR\_EXAM** |  |  |  | 0.73 | Chi-square |
| NO | 6(7.8%) | 4(7.1%) | 2(9.5%) |  |  |
| YES | 71(92.2%) | 52(92.9%) | 19(90.5%) |  |  |
| **OR\_DENTAL\_EX** |  |  |  | <0.01 | Chi-square |
| NO | 70(90.9%) | 56(100.0%) | 14(66.7%) |  |  |
| YES | 7(9.1%) | 0 | 7(33.3%) |  |  |
| **ORAL\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 1.0(0.0-3.0) | 1.0(0.0-2.0) | 2.0(0.0-3.0) |  |  |
| **RES\_EXAM** |  |  |  | 0.28 | Chi-square |
| NO | 3(3.9%) | 3(5.4%) | 0 |  |  |
| YES | 74(96.1%) | 53(94.6%) | 21(100.0%) |  |  |
| **RES\_TOBACCO** |  |  |  | 0.09 | Chi-square |
| NO | 72(93.5%) | 54(96.4%) | 18(85.7%) |  |  |
| YES | 5(6.5%) | 2(3.6%) | 3(14.3%) |  |  |
| **RES\_SYM\_ASS** |  |  |  | 0.54 | Chi-square |
| NO | 1(1.3%) | 1(1.8%) | 0 |  |  |
| YES | 76(98.7%) | 55(98.2%) | 21(100.0%) |  |  |
| **RES\_PFT** |  |  |  | 0.46 | Chi-square |
| NO | 2(2.6%) | 1(1.8%) | 1(4.8%) |  |  |
| YES | 75(97.4%) | 55(98.2%) | 20(95.2%) |  |  |
| **RESP\_SCORE** |  |  |  | 0.16 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 3.0(1.0-4.0) | 3.0(1.0-4.0) | 3.0(2.0-4.0) |  |  |
| **CV\_EXAM** |  |  |  | 0.28 | Chi-square |
| NO | 3(3.9%) | 3(5.4%) | 0 |  |  |
| YES | 74(96.1%) | 53(94.6%) | 21(100.0%) |  |  |
| **CV\_RISK\_EVAL** |  |  |  | <0.01 | Chi-square |
| NO | 49(63.6%) | 41(73.2%) | 8(38.1%) |  |  |
| YES | 28(36.4%) | 15(26.8%) | 13(61.9%) |  |  |
| **CV\_ED** |  |  |  | <0.01 | Chi-square |
| NO | 66(85.7%) | 52(92.9%) | 14(66.7%) |  |  |
| YES | 11(14.3%) | 4(7.1%) | 7(33.3%) |  |  |
| **CV\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 1.0(0.0-3.0) | 1.0(0.0-3.0) | 2.0(1.0-3.0) |  |  |
| **HEP\_HEPBC** |  |  |  | 0.71 | Chi-square |
| NO | 72(93.5%) | 52(92.9%) | 20(95.2%) |  |  |
| YES | 5(6.5%) | 4(7.1%) | 1(4.8%) |  |  |
| **HEP\_VIRALLOAD** |  |  |  | 0.38 | Chi-square |
| NO | 75(97.4%) | 54(96.4%) | 21(100.0%) |  |  |
| YES | 2(2.6%) | 2(3.6%) | 0 |  |  |
| **HEP\_FERRITIN\_ASS** |  |  |  | 0.61 | Chi-square |
| NO | 65(84.4%) | 48(85.7%) | 17(81.0%) |  |  |
| YES | 12(15.6%) | 8(14.3%) | 4(19.0%) |  |  |
| **HEP\_FERRTIN\_OR\_PREABNL** |  |  |  | 0.28 | Chi-square |
| NO CHCK 4 ABNORMAL | 3(3.9%) | 1(1.8%) | 2(9.5%) |  |  |
| NO | 64(83.1%) | 48(85.7%) | 16(76.2%) |  |  |
| YES | 10(13.0%) | 7(12.5%) | 3(14.3%) |  |  |
| **HEPA\_SCORE** |  |  |  | 0.73 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 0.0(0.0-4.0) | 0.0(0.0-4.0) | 0.0(0.0-2.0) |  |  |
| **RENAL\_BP** | All patients got YES |  |  |  |  |
| **RENAL\_BUN\_CR** | All patients got YES |  |  |  |  |
| **RENAL\_SCORE** |  |  |  | 1.00 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 2.0(2.0-2.0) | 2.0(2.0-2.0) | 2.0(2.0-2.0) |  |  |
| **MS\_EVAL\_MS\_WEAKNESS** |  |  |  | 0.13 | Chi-square |
| NO | 69(89.6%) | 52(92.9%) | 17(81.0%) |  |  |
| YES | 8(10.4%) | 4(7.1%) | 4(19.0%) |  |  |
| **MS\_COUNSEL\_PHY** |  |  |  | 0.04 | Chi-square |
| NO | 68(88.3%) | 52(92.9%) | 16(76.2%) |  |  |
| YES | 9(11.7%) | 4(7.1%) | 5(23.8%) |  |  |
| **MS\_COUNSEL\_ON\_FALL** |  |  |  | 0.10 | Chi-square |
| NO | 76(98.7%) | 56(100.0%) | 20(95.2%) |  |  |
| YES | 1(1.3%) | 0 | 1(4.8%) |  |  |
| **MS\_COUNSEL\_CA\_VITD** |  |  |  | <0.01 | Chi-square |
| NO | 61(79.2%) | 50(89.3%) | 11(52.4%) |  |  |
| YES | 16(20.8%) | 6(10.7%) | 10(47.6%) |  |  |
| **MS\_ASS\_NEED\_DEXA** |  |  |  | <0.01 | Chi-square |
| NO | 61(79.2%) | 50(89.3%) | 11(52.4%) |  |  |
| YES | 16(20.8%) | 6(10.7%) | 10(47.6%) |  |  |
| **MS\_DEXA** |  |  |  | <0.01 | Chi-square |
| NO | 61(79.2%) | 49(87.5%) | 12(57.1%) |  |  |
| YES | 16(20.8%) | 7(12.5%) | 9(42.9%) |  |  |
| **MS\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 0.0(0.0-5.0) | 0.0(0.0-4.0) | 2.0(0.0-5.0) |  |  |
| **CNS\_EXAM** |  |  |  | <0.01 | Chi-square |
| NO | 30(39.0%) | 28(50.0%) | 2(9.5%) |  |  |
| YES | 47(61.0%) | 28(50.0%) | 19(90.5%) |  |  |
| **CNS\_EVAL\_COGNITIVE** |  |  |  | 0.12 | Chi-square |
| NO | 74(96.1%) | 55(98.2%) | 19(90.5%) |  |  |
| YES | 3(3.9%) | 1(1.8%) | 2(9.5%) |  |  |
| **CNS\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 1.0(0.0-2.0) | 0.5(0.0-2.0) | 1.0(0.0-2.0) |  |  |
| **ENDO\_TFT** |  |  |  | 0.09 | Chi-square |
| NO | 22(28.6%) | 19(33.9%) | 3(14.3%) |  |  |
| YES | 55(71.4%) | 37(66.1%) | 18(85.7%) |  |  |
| **ENDO\_ASS\_GONADAL\_FUNCTION** |  |  |  | 0.66 | Chi-square |
| NO | 68(88.3%) | 50(89.3%) | 18(85.7%) |  |  |
| YES | 9(11.7%) | 6(10.7%) | 3(14.3%) |  |  |
| **ENDO\_GONADAL\_FN\_TEST** |  |  |  | 0.94 | Chi-square |
| NO | 70(90.9%) | 51(91.1%) | 19(90.5%) |  |  |
| YES | 7(9.1%) | 5(8.9%) | 2(9.5%) |  |  |
| **ENDO\_SCORE** |  |  |  | 0.15 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 1.0(0.0-3.0) | 1.0(0.0-3.0) | 1.0(0.0-3.0) |  |  |
| **MUCU\_SKINEXAM** |  |  |  | 0.16 | Chi-square |
| NO | 24(31.2%) | 20(35.7%) | 4(19.0%) |  |  |
| YES | 53(68.8%) | 36(64.3%) | 17(81.0%) |  |  |
| **MUCU\_COUNSEL\_SUN\_EXPOSURE** |  |  |  | <0.01 | Chi-square |
| NO | 70(90.9%) | 56(100.0%) | 14(66.7%) |  |  |
| YES | 7(9.1%) | 0 | 7(33.3%) |  |  |
| **MU\_CU\_GYNE\_EXAM** |  |  |  | <0.01 | Chi-square |
| NO | 74(96.1%) | 56(100.0%) | 18(85.7%) |  |  |
| YES | 3(3.9%) | 0 | 3(14.3%) |  |  |
| **MUCU\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 1.0(0.0-3.0) | 1.0(0.0-1.0) | 1.0(0.0-3.0) |  |  |
| **SECOND\_\_CANCER\_COUNSEL** |  |  |  | <0.01 | Chi-square |
| NO | 67(87.0%) | 52(92.9%) | 15(71.4%) |  |  |
| YES | 10(13.0%) | 4(7.1%) | 6(28.6%) |  |  |
| **SECOND\_CANCER\_SCREENING** |  |  |  | <0.01 | Chi-square |
| NO | 66(85.7%) | 52(92.9%) | 14(66.7%) |  |  |
| YES | 11(14.3%) | 4(7.1%) | 7(33.3%) |  |  |
| **SECOND\_CANCER\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 0.0(0.0-2.0) | 0.0(0.0-2.0) | 0.0(0.0-2.0) |  |  |
| **PSYCH\_QOL\_SCREENING** |  |  |  | 0.29 | Chi-square |
| NO | 73(94.8%) | 54(96.4%) | 19(90.5%) |  |  |
| YES | 4(5.2%) | 2(3.6%) | 2(9.5%) |  |  |
| **PSYCH\_INQUIRY\_FAMILY** |  |  |  | 0.54 | Chi-square |
| NO | 76(98.7%) | 55(98.2%) | 21(100.0%) |  |  |
| YES | 1(1.3%) | 1(1.8%) | 0 |  |  |
| **PSYCH\_INQUIRY\_SEXUAL\_FUNCTION** |  |  |  | 0.10 | Chi-square |
| NO | 76(98.7%) | 56(100.0%) | 20(95.2%) |  |  |
| YES | 1(1.3%) | 0 | 1(4.8%) |  |  |
| **PSYCH\_INQUIRY\_SUBSTANCE\_ABUSE** |  |  |  | 0.54 | Chi-square |
| NO | 76(98.7%) | 55(98.2%) | 21(100.0%) |  |  |
| YES | 1(1.3%) | 1(1.8%) | 0 |  |  |
| **PSYCH\_SCORE** |  |  |  | 0.33 | Rank-Sum Tests |
| N of Observed | 77 | 56 | 21 |  |  |
| Median(Min-Max) | 0.0(0.0-1.0) | 0.0(0.0-1.0) | 0.0(0.0-1.0) |  |  |
|  |  |  |  |  |  |